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Abstract
Rationale—Fetuses that develop in diabetic mothers have a higher incidence of birth defects that
include cardiovascular defects, but the signaling pathways that mediate these developmental
effects are poorly understood. It is reasonable to hypothesize that diabetic maternal effects are
mediated by one or more pathways activated downstream of aberrant glucose metabolism, since
poorly controlled maternal glucose levels correlate with the frequency and severity of the defects.
Objective—We asked whether RasGRP3, a Ras activator expressed in developing blood vessels,
mediates diabetes-induced vascular developmental defects.
RasGRP3 is activated by diacylglycerol (DAG), and DAG is over-produced by aberrant glucose
metabolism in diabetic individuals. We also investigated the effects of over-activation and loss-of-
function for RasGRP3 in primary endothelial cells and developing vessels.
Methods and Results—Analysis of mouse embryos from diabetic mothers showed that
diabetes-induced developmental defects were dramatically attenuated in embryos lacking Rasgrp3
function. Endothelial cells that expressed activated RasGRP3 had elevated Ras-ERK signaling and
perturbed migration, while endothelial cells lacking Rasgrp3 function had attenuated Ras-ERK
signaling and did not migrate in response to endothelin-1.
Developing blood vessels exhibited endothelin-stimulated vessel dysmorphogenesis that required
Rasgrp3 function.
5Corresponding author: Victoria L Bautch Professor of Biology Department of Biology, CB#3280 University of North Carolina at
Chapel Hill Chapel Hill, NC 27599 USA Phone: 919-966-6797 Fax: 919-962-8472 bautch@med.unc.edu.
^current address: Dept. of Pathology, Technical University, Dresden, Germany
@current address: Dept. of Pathology, Yale University, New Haven CT
#current address: Pfizer Inc, Groton CT
&current address: Dept. of Biology, Franklin and Marshall College, Lancaster, PA 17604
*These authors contributed equally to the work
DISCLOSURES
None.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Circ Res. Author manuscript; available in PMC 2013 July 12.
Published in final edited form as:













Conclusions—These findings provide the first evidence that RasGRP3 contributes to
developmental defects found in embryos developing in a diabetic environment. The results also
elucidate RasGRP3-mediated signaling in endothelial cells, and identify endothelin-1 as an
upstream input and Ras/MEK/ERK as a downstream effector pathway. RasGRP3 may be a novel
therapeutic target for the fetal complications of diabetes.
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INTRODUCTION
Receptor-mediated signaling is required for endothelial cell proliferation and migration,
processes that are critical to blood vessel formation and function 1. Signaling downstream of
receptor engagement in endothelial cells leads to the activation of several pathways,
including PLCγactivation to produce diacylglycerol (DAG). DAG in turn activates
downstream targets to affect endothelial cell behaviors. Signals that are up-regulated in
diabetes, such as VEGF-A and endothelin-1 (ET1), generate DAG. DAG is also produced
by aberrant glucose metabolism, and DAG levels are elevated in diabetic animals and
patients 2, 3. Diabetic individuals have compromised angiogenesis and blood vessel function,
and fetuses of diabetic mothers have an increased incidence of birth defects, including
vascular defects 3, 4. It is assumed that these vascular defects are mediated, at least in part,
by elevated DAG levels, since mouse embryos recovered from diabetic mothers had
elevated DAG levels and increased developmental defects 3. However, it is not fully
understood how elevated DAG leads to vessel dysfunction.
The effects of DAG on cell signaling are mimicked by phorbol esters, tumor promoters that
also affect endothelial proliferation, cellular morphology, apoptosis, and barrier function 5-9.
DAG and phorbol esters are potent activators of the PKC family of proteins. Numerous
mammalian PKC isoforms fall into several sub-families, and DAG/phorbol esters activate
PKC signaling by binding to C1 domains found in the classic (PKCα, β, γ) and novel
(PKCδ, ε, η, θ) sub-groups of PKCs 10. Recently several non-PKC protein families were
identified that contain C1 domains and respond to DAG and phorbol esters, suggesting that
some DAG/phorbol ester-mediated responses require these proteins 11.
RasGRPs are non-PKC DAG/phorbol ester receptors that function as guanine nucleotide
exchange factors (GEFs) and activate the Ras family of GTPases 12, 13. Ras proteins are
localized to membranes, and their activation is controlled in part by proximity to GEFs, such
that recruitment of GEFs to membranes can activate Ras. Both DAG and phorbol esters
recruit RasGRPs to membranes via the C1 domain. Active Ras in turn activates several
effector pathways such as MEK/ERK, p38 MAPK, and JNK. Ras proteins are activated by
phorbol esters in cultured endothelial cells 14, and PKCs also contribute to Ras and ERK
activation in response to phorbol esters in endothelial cells; however, the potential role of
non-PKC DAG/phorbol ester receptors in this response has not been investigated.
The RasGRP family of non-PKC phorbol ester receptors has 4 family members. The
RasGRPs have limited sites of expression in vivo, and genetic deletion experiments reveal a
non-redundant function for the RasGRPs in hematopoietic and endothelial cells. RasGRP1
transduces signals downstream of the T cell receptor for T cell maturation, and both
RasGRP1 and RasGRP3 affect B cell function in complex ways 15-17. RasGRP2 was
recently reported to have effects on vascular development in Xenopus 18. We identified
RasGRP3 in a murine-based gene-trap screen as a locus expressed in endothelial cells of
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developing vessels and required for mediating the endothelial cell effects of DAG/phorbol
esters 19. The expression profile and DAG/phorbol ester interactions suggested that
RasGRP3 might mediate the effects of excess DAG on developing vessels in diabetes.
RasGRP3 activates Ras, Rap, and R-ras in vitro and in mouse embryo fibroblasts 20. In
addition to requiring DAG/phorbol ester activity for membrane localization 21, RasGRP3 is
phosphorylated by PKC at Thr133, and this phosphorylation is required for RasGRP3
activity in B cells 22, 23. RasGRP3 also binds dynein light chain, a component of a
microtubule plus-end directed motor, but the significance of this binding in vivo is not
clear 24. We showed that RasGRP3 is expressed in angiogenic vessels. Although a genetic
loss-of-function generated by the gene trap did not affect development, embryonic vessels
exposed to phorbol ester exhibited dysmorphogenesis that required Rasgrp3 function,
identifying RasGRP3 as a novel endothelial phorbol ester receptor 19. Here we further
characterize the role of RasGRP3-mediated Ras signaling in embryos, endothelial cells, and
developing vessels. We find that loss of Rasgrp3 function significantly reduces diabetes-
induced birth defects in vivo, including embryonic vascular defects. We show that Ras is a
target of RasGRP3 in endothelial cells, and that RasGRP3 is required for ET1-mediated
effects on vessel morphogenesis. Our data are consistent with a model in which RasGRP3
signaling in embryonic endothelial cells transduces signals downstream of DAG that affect
endothelial cell behaviors and lead to vessel dysmorphogenesis. Thus excess DAG in
diabetes likely over-activates RasGRP3, and this contributes to the perturbed development
of fetuses in diabetic environments.
MATERIALS AND METHODS
Diabetic mice and embryo analysis
Female mice (C57Bl/6J purchased from Jackson Laboratories, or Rasgrp3gt/gt (a loss-of-
function null mutation 19) backcrossed to N8 on the C57Bl/6J background) at 6-8 weeks of
age were made diabetic following the protocol in “Animal Models of Diabetic
Complications Consortium”. Alternatively, Ins2Akita/+ mice on the C57Bl6/J background
(Jackson Laboratories, #003548) were bred to obtain Ins2Akita/+; Rasgrp3gt/gt mice. Blood
glucose was monitored weekly, and mice with blood glucose levels over 250 mg/dL were
considered diabetic. Mice were mated to genotype-matched males, embryos were harvested
at E9.5, fixed, and whole mount stained for PECAM as described 25. Stained embryos were
imaged and scored for defects as described (Supplemental Methods).
Whole embryo culture was done on embryos dissected at E7.5 or E8.5, in roller bottles as
described 26. Some embryos were treated with 50nM PMA (phorbol 12-myristate 13-
acetate) and some with 20 mM glucose during the culture period. After 24 hr, embryos were
removed and photographed.
Endothelial cells
HUVEC were purchased from Clonetics, cultured according to manufacturer's protocol, and
used between passages 2-8. Transfections were done using an Amaxa nucleofector
according to directions. For staining, cells were fixed, permeabilized, blocked, and
incubated with phalloidin-Alexa 555 (Molecular Probes). Migration assays were carried out
48 hr post-transfection as described (Supplemental Methods). Average velocity and distance
to origin of cells was calculated using trajectory measures as diagrammed in Fig. 3J.
Mouse endothelial cells (wildtype and Rasgrp3gt/gt) were generated and expanded as
described 27, 28, with minor modifications. Proliferation assays and migration assays were as
described (Supplemental Methods).
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ES cell differentiation and analysis
Wild type (WT, +/+) and RasGRP3 deficient (Rasgrp3gt/gt) ES cells were maintained and
differentiated for 8 days as previously described 29. For inhibitor studies, day 7 ES cell
cultures were pre-treated with the appropriate inhibitor for 2 hr prior to addition of 100 nM
PMA for 24 hr. For ET1 stimulation, 100 nM ET1 in fresh medium was added daily
between days 5-8. Antibody staining of ES cell cultures was as previously described 25, 29.
Quantitative image analysis of PECAM-stained ES cell cultures was performed as
previously described 25.
Ras and ERK activation assays
HUVEC (50-80% transfected by GFP labeling after transfection) or mouse endothelial cells
were grown to near confluency for 48 hr, serum starved overnight, then processed as
described (Supplemental Methods) for Ras-GTP immunoprecipitation, or total Ras, pERK,
or total ERK Western blots.
RESULTS
Loss of Rasgrp3 protects embryos from diabetes-induced birth defects
Because RasGRP3 is expressed in developing vessels and somites of mid-gestation mouse
embryos 19, we reasoned that embryos exposed to elevated DAG signaling would be
susceptible to effects of RasGRP3-mediated signaling in vivo. Thus we examined the effects
of elevated DAG/phorbol ester, glucose, and the diabetic environment on these stages of
mouse development. We first mimicked elevated DAG signaling by incubating mouse
embryos harvested at E7.5 for 24 hr. in phorbol ester under whole embryo culture conditions
(Online Fig. I). WT embryos exposed to PMA were severely affected (Online Fig. I, A-D),
with loss of anterior-posterior landmarks, and yolk sacs with large cavities. In contrast,
Rasgrp3gt/gt mutant embryos incubated under the same conditions were surprisingly intact,
and anterior-posterior landmarks were evident, along with intact yolk sacs (Online Fig. I, E-
H). We next incubated embryos in 20 mM glucose for 24 hr to mimic the diabetic
environment (Online Fig II). Glucose exposure between E8.5 and E9.5 led to vascular
defects in WT embryos, and likely non-vascular defects such as perturbed somitogenesis and
axis defects as well. In contrast, Rasgrp3gt/gt mutant embryos were relatively refractory to
the teratogenic effects of elevated glucose.
To more precisely define the effects of a diabetic environment on developing embryos, we
induced diabetes in female mice, then set up matings and examined embryos. On an outbred
background, WT embryos often showed quite severe defects, including aberrant somite
formation and vessel patterning, relative to Rasgrp3gt/gt mutant embryos (Online Fig. III).
To make more rigorous comparisons, we next examined embryos on the C57Bl6/J inbred
background. We induced diabetes chemically via STZ, and we also utilized mice carrying
the Ins2Akita mutation that induces diabetes genetically. We monitored the average maternal
blood glucose at sacrifice via tail bleed, and found the following values: WT STZ, 381 mg/
dl; Rasgrp3gt/gt STZ, 448 mg/dl; Ins2Akita; Rasgrp3gt/gt 387 mg/dl). Embryos were harvested
from diabetic mothers at E9.5, whole-mount stained for PECAM to visualize vessel
development and patterning, and the severity of defects in head plexus vessels, intersomitic
vessels, and trunk/somite scored as described in the Methods (Fig. 1). WT embryos from
diabetic mothers induced either chemically or genetically had a significantly elevated
developmental severity index compared to controls (Fig. 1 A-B, E, O; Online Fig. IV).
Closer examination of the somite region showed defects in somites and in the pattern of
intersomitic vessels (Fig. 1 G-J), and similar defects were seen in the vascular plexus of the
head (Fig. 1 K-N). In contrast, embryos similarly developing in diabetic mothers but
genetically deficient for Rasgrp3 appeared relatively unaffected, and their developmental
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severity index was significantly lower than WT counterparts, and close to control levels
(Fig. 1, C-N, O; Online Fig. IV). Analysis of yolk sacs from these embryos showed a low
level of vascular defects that did not significantly correlate with genotype, diabetic
condition, or the severity of the corresponding embryo (Online Fig. V and data not shown).
Thus loss of Rasgrp3 function has a protective effect on diabetes-induced developmental
defects, including vascular defects, suggesting that DAG-mediated activation of RasGRP3
mediates diabetes-induced birth defects.
Ras is a target of RasGRP3 in endothelial cells
To explore how RasGRP3 signaling contributes to diabetes-induced developmental defects,
we first analyzed signaling in HUVEC that up-regulated RasGRP3 activity, because the
developmental defects are predicted to result from over-activation of RasGRP3 by DAG
(Fig. 2). Wild-type RasGRP3 linked to a GFP reporter, and constructs in which a K-Ras
CAAX or H-Ras CAAX sequence was linked to the protein, were transiently expressed in
HUVEC (Fig. 2A). The CAAX sequences localize RasGRP3 to membranes 20, which
mimics DAG-promoted activation to place the activator in physical proximity to Ras. Thus
these constructs are predicted to be “constitutively active” in terms of their action on Ras
and provide gain-of-function activity independent of any over-expression effects. Over-
expression of WT RasGRP3 did not significantly increase Ras activation over baseline, but
both of the CAAX tagged RasGRP3 proteins stimulated significant Ras activation (Fig. 2B,
C). ERK activation is downstream of Ras activation, and in HUVEC both CAAX-tagged
RasGRP3 proteins also significantly induced ERK activation (Fig. 2B, C). These data
indicate that Ras is a target of RasGRP3 in endothelial cells.
To examine the cellular responses of endothelial cells to RasGRP3-mediated signaling, we
examined the effects of RasGRP3 over-activation on the cytoskeleton, since in other cell
types Ras activation affects the cytoskeleton 30, 31. HUVEC expressing the constructs
described above were stained for microtubules (α-tubulin, data not shown) and actin
(phalloidin) (Fig. 3A-H). The microtubule staining pattern was not affected by over-
expression of RasGRP3 (data not shown); however, the actin cytoskeleton was dramatically
altered in endothelial cells over-expressing membrane-localized RasGRP3 (Fig. 3E-H).
RasGRP3-CAAX expressing cells appeared larger and flatter, and they had very few actin
stress fibers. Cortical actin was also diminished in endothelial cells over-expressing
RasGRP3-CAAX. Since actin stress fibers are implicated in proper migration, we
investigated the migratory behavior of endothelial cells over-expressing RasGRP3 (Fig. 3I-
L). Endothelial cells over-expressing RasGRP3 were identified by GFP expression, and all
cells were labeled with cell-tracker (Fig. 3I). Cells were imaged, and the average velocity
and distance migrated from origin was calculated as described in methods (Fig. 3J). None of
the RasGRP3 proteins affected the overall velocity of the cells, but the CAAX-tagged
RasGRP3 proteins both significantly inhibited the distance migrated from the origin (Fig.
3K-L). These results show that endothelial cells that over-express membrane-localized (and
thus activated) RasGRP3 have a perturbed actin cytoskeleton, and an attenuated ability to
migrate in a forward direction.
To investigate the effects of loss-of-function for Rasgrp3 on signaling pathway(s),
endothelial cells were isolated and immortalized from WT and Rasgrp3gt/gt mice. The cells
were expanded clonally, and the endothelial identity of the cells verified by expression of
endothelial markers. The cell lines were greater than 95% positive for PECAM, VE-
cadherin, and ICAM-2 (Online Fig. VI, A-D and data not shown). RT-PCR analysis showed
loss of RasGRP3 expression in Rasgrp3gt/gt endothelial cells, and growth curves showed that
WT and Rasgrp3gt/gt endothelial cell grew at similar rates (Online Fig. VI, E-F).
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We asked whether RasGRP3 was necessary for Ras and ERK activation downstream of
DAG/phorbol ester stimulation. WT and Rasgrp3gt/gt endothelial cells incubated with PMA
were evaluated for changes in the levels of Ras and ERK activation. WT endothelial cells
stimulated with PMA had elevated levels of active Ras and active ERK. In contrast,
Rasgrp3gt/gt endothelial cells stimulated with PMA showed no detectable Ras activation, and
ERK activation was attenuated (Fig. 4A, Online Fig. X, A). These results reveal a
requirement for RasGRP3 in Ras/ERK signaling downstream of DAG/phorbol ester
stimulation in endothelial cells.
We next examined the signaling requirements downstream of RasGRP3 activation in
endothelial cells of developing vessels, utilizing a mouse embryonic stem (ES) cell
differentiation model that supports the formation of primitive blood vessels in vitro via a
programmed differentiation 29, 32, 33. We previously showed that ES cell-derived blood
vessels respond to phorbol ester stimulation with a dramatic vessel dysmorphogenesis that is
dependent on Rasgrp3 function 19 (Online Fig. VII, A-D). We therefore asked whether
signaling downstream of activated RasGRP3 in developing vessels utilized the Ras effector
pathways MEK/ERK, p38 MAPK or JNK. The vessel dysmorphogenesis seen upon PMA
stimulation was significantly attenuated in the presence of the MEK inhibitor U0126 (Online
Fig. VII, E-F, I). In contrast, the p38 MAP kinase inhibitor SB203580 had no effect on
PMA-induced vessel dysmorphogenesis (Online Fig. VII, G-H, I), and the JNK inhibitor
SP600125 showed a similar lack of effect (data not shown). Thus RasGRP3-dependent
DAG/phorbol ester signaling in developing vessels requires MEK but not p38 MAPK or
JNK downstream of Ras GTPases.
Activation of RasGRP3 in B cells requires, in addition to membrane localization,
phosphorylation by PKC. To test PKC function in endothelial cells, we exposed ES-derived
vessels to PKC inhibitors concomitant with exposure to phorbol ester (Online Fig. VIII). A
general inhibitor of most PKC isoforms, BIM (bisindolymaleimide), targets the kinase
activity of PKC and not C1 domain interactions; thus BIM inhibits PKC activation without
affecting C1-domain mediated RasGRP3 activation. BIM completely blocked phorbol ester
induced vessel dysmorphogenesis (Online Fig. VIII, C-D, I). Likewise, an inhibitor of the
conventional PKC isoforms α and β, Gö6976, completely blocked PMA-induced vessel
dysmporphogenesis (Online Fig. VIII, E-F, I). A third PKC inhibitor, rottlerin,
predominantly affects PKCδ, and it partially blocked PMA-induced vessel
dysmorphogenesis (Online Fig. VIII, G-H, I). These results show a requirement for PKC
activity in phorbol ester-induced vessel dysmorphogenesis, and suggest that endothelial
RasGRP3 requires activation by PKC phosphorylation.
RasGRP3 is required for ET1-mediated Ras and ERK signaling in endothelial cells
Although phorbol ester mimics endogenous DAG production and signaling downstream of
physiological inputs, it does not identify the physiological signal(s) that normally activate
RasGRP3-dependent signaling in endothelial cells. To identify physiologically relevant
signals upstream of RasGRP3 in endothelial cells, we investigated signaling mediated by
VEGF-A and ET1, two angiogenic factors that utilize DAG-Ras-ERK downstream
signaling. WT and Rasgrp3gt/gt endothelial cells were stimulated with VEGF or ET1, and
levels of active Ras and ERK analyzed (Fig. 4B-C, Online Fig. X, B). As predicted, WT
endothelial cells had increased levels of active Ras and ERK upon treatment with either
VEGF or ET1. In contrast, while Rasgrp3gt/gt endothelial cells had elevated levels of active
Ras and ERK with VEGF treatment, they showed no increase in active Ras and attenuated
active ERK with ET1 stimulation. Thus, RasGRP3 is required for Ras and ERK activation
downstream of ET1 stimulation in endothelial cells. These results identify ET1 as a
physiological signal for RasGRP3-mediated signaling in endothelial cells.
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RasGRP3 is required for ET1-induced stimulation of endothelial cell proliferation and
migration
Activation of Ras-ERK signaling by ET1 stimulates endothelial cell proliferation and
migration 34. To determine whether ET1-induced endothelial cell proliferation and
migration were RasGRP3-dependent, WT and Rasgrp3gt/gt endothelial cells were treated
with ET1 and evaluated. WT endothelial cells exhibited over a 2-fold increase in mitotic
index over baseline with ET1 treatment, while Rasgrp3gt/gt endothelial cells did not exhibit a
significant change in their mitotic index with ET1 treatment (Fig. 5A-E). In a Boyden
chamber migration assay, VEGF induced migration of both WT and Rasgrp3gt/gt endothelial
cells significantly and to a similar degree. However, ET1 only stimulated migration of WT
endothelial cells, and did not significantly induce migration of Rasgrp3gt/gt endothelial cells
(Fig. 5F). These results indicate that ET1-induced proliferation and migration require
Rasgrp3 function, whereas VEGF-induced migration occurs independent of RasGRP3.
RasGRP3 mediates vessel dysmorphogenesis induced by ET1
Since both ET1-induced endothelial cell proliferation and migration are RasGRP3-
dependent, we asked whether ES cell-derived blood vessels had RasGRP3-dependent
dysmorphogenesis induced by ET1 (Fig. 6). ET1 treatment of WT vessels led to loss of the
fine vascular network and significantly increased vascular area (Fig. 6A-B, E). This
response was Rasgrp3-dependent, as Rasgrp3gt/gt vessels retained the fine vascular network
and did not exhibit increased vascular area under with ET1 treatment (Fig. 6C-D, E). ET1-
mediated vessel dysmorphogenesis was also dependent on PKC activity, since PKC
inhibition blocked ET1 effects on vessels (Online Fig. IX). Thus developing vessels exhibit
vessel dysmorphogenesis in response to ET1, and that response requires RasGRP3 and PKC
function. Taken together, these data suggest that RasGRP3 is required for ET1-induced
endothelial cell angiogenic responses.
DISCUSSION
RasGRP3 is an activator of Ras family GTPases that is expressed in angiogenic vessels and
required for the DAG/phorbol ester-mediated responses of these vessels. Here we posit that
RasGRP3 is over-activated in embryos developing in a diabetic environment and susceptible
to birth defects, and we show that loss of RasGRP3 significantly attenuates the detrimental
effects of a diabetic environment on embryonic vascular development. We also define the
molecular and cellular processes perturbed by DAG/phorbol ester-induced activation of
RasGRP3 activation in endothelial cells of developing vessels. We define ET1 as an
upstream input and Ras as a target of RasGRP3 in endothelial cells, and we show that
manipulation of RasGRP3 perturbs endothelial migration. These data lead to a model of
RasGRP3-mediated signaling in endothelial cells that includes a molecular mechanism,
cellular phenotype, and effects on the developing embryo in a diabetic environment (Fig. 7).
We activated RasGRP3 in developing vessels using phorbol ester as a DAG mimic, and
RasGRP3-dependent vessel dysmorphogenesis required MEK/ERK signaling. Our data
indicates that Ras is a primary target of RasGRP3 in endothelial cells, since over-expression
of RasGRP3 linked to either K-Ras CAAX or H-Ras CAAX domains significantly activated
both Ras and ERK, while loss-of-function analysis showed that RasGRP3 was required for
ET1- or DAG/phorbol ester-mediated Ras and MEK/ERK activation. Our data do not rule
out that RasGRP3 activates other Ras GTPases in endothelial cells, but they suggest that
signaling through Ras to MEK/ERK is critical for the vascular response to DAG. RasGRP3
is normally activated by both localization to membranes via DAG binding to its C1 domain
and by PKC phosphorylation 12. Over-expression of RasGRP3 alone was not sufficient to
activate endothelial Ras, but over-expression of membrane localized forms was sufficient
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for activation, suggesting that endogenous PKC levels are not rate-limiting for RasGRP3
activation in endothelial cells. Our studies also reveal a requirement for classical/novel PKC
isoform activity in the response of developing vessels to DAG/phorbol esters and ET1.
While it is possible that the PKC requirement is downstream of the genetic requirement for
RasGRP3, we favor the hypothesis that PKC phosphorylation of RasGRP3 is required for its
activity in endothelial cells, as has been shown in B cells 22, 23.
Elevated RasGRP3 activity affects specific cellular responses of endothelial cells.
Endothelial cells that over-express activated RasGRP3 are flattened relative to controls, a
phenotype also observed in neural cells expressing activated RasGRP3 20. Consistent with
this phenotype, the actin cytoskeleton is perturbed in these cells, with loss of stress fibers
and reduction of the cortical actin ring. The perturbation of the actin cytoskeleton in
endothelial cells that over-express RasGRP3 is similar to actin perturbations seen in tumor
cells that express activated Ras 35-37. In general, Ras activation reduces actin stress fiber
formation, primarily through effects on RhoA activity, but also via MEK signaling to
ERK1/2 and ERK5 30, 31, 38. Actin stress fibers link to focal adhesions on the ventral side of
cells, and this linkage promotes acto-myosin contractility 39, 40. In terms of migration, stress
fibers are thought to act as rudders that keep cells migrating directionally 41, 42. Consistent
with this idea, we find that endothelial cells over-expressing activated RasGRP3 have
normal velocity but significantly reduced migration relative to the origin over time. This
finding suggests that the cells can move, but their ability to link one movement to the next in
a coordinated fashion is impaired. Thus over-expression of activated RasGRP3 mimics Ras
over-activation and prevents orderly forward migration of endothelial cells.
Complementary loss-of-function analysis showed that Rasgrp3 function is required for
DAG/phorbol ester mediated Ras activation, as is predicted to occur in diabetic
environments with elevated DAG levels. Interestingly, RasGRP3 is involved in Ras/ERK
signaling downstream of ET1 in endothelial cells. ET1 is elevated in diabetic milieus 43 and
leads to DAG production, so perhaps two sources of DAG – DAG produced via elevated
glucose and DAG produced via elevated ET1 signaling, contribute to RasGRP3-mediated
vascular pathologies in diabetic animals. In contrast, a second signal that is elevated in
diabetic environments, VEGF-A, does not appear to require RasGRP3 for Ras-mediated
signaling, although RasGRP3 expression is up-regulated by VEGF-A 19. Several studies
reported that ET1 angiogenic effects required VEGF-A 44, 45. In light of our work, it is
possible that this VEGF-A requirement reflects a need for VEGF-A-stimulated RasGRP3
expression. Thus the requirement for RasGRP3 in ET1-mediated signaling may link the
activities of the two pathways in diabetes.
Because diabetes is accompanied by elevated DAG levels and leads to developmental
defects, including vascular defects, we hypothesized that in a diabetic fetal environment
elevated maternal glucose crosses the placenta, where it is metabolized to DAG. The excess
DAG ectopically activates embryonic RasGRP3, and downstream activation of Ras
signaling contributes to the increased incidence of developmental problems. This hypothesis
predicts that embryos lacking Rasgrp3 are less susceptible to diabetes-induced birth defects,
and in fact embryos lacking Rasgrp3 were significantly protected from developmental
defects produced in a diabetic fetal environment. This was true whether the mothers were
diabetic from STZ destruction of pancreatic β cells or via the Ins2Akita mutation, which
inactivates the insulin II gene and thus leads to diabetes 46. The embryonic defects we
documented were similar to the defects reported by others 3, 4. Interestingly, embryos that
lacked Rasgp3 function and developed in diabetic mothers had significantly fewer defects in
developing somites and developing vessels, two embryonic organs that express RasGRP3 19.
The vascular defects seen in WT embryos from diabetic mothers were consistent with the
endothelial migration defects observed in primary endothelial cells, since the intersomitic
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vessels were sometimes blunted, with expanded migratory fronts. Interestingly, while yolk
sac vessels showed some pattern defects, these did not significantly correlate with embryo
genotype, diabetic environment, or overall embryo defects, in contrast to another group who
described significant diabetes-induced yolk sac vasculopathy 4, 47. This indicates that the
observed diabetes-induced embryonic defects were not secondary to yolk sac defects that
compromised overall embryonic health.
Was the protection afforded by loss of RasGRP3 from the maternal compartment, the
embryonic compartment, or both? Several lines of evidence support a critical role for
embryonic Rasgrp3 function in mediating the effects of diabetes. First, another study
showed that DAG levels and activated PKC are elevated in embryos from diabetic
mothers 3, indicating that upstream requirements for RasGRP3 activation are in place in the
embryo. In our work, mothers lacking RasGRP3 became diabetic, and their average blood
glucose at sacrifice was higher than WT controls. Whole embryo culture using medium
supplemented with PMA showed that embryos lacking Rasgrp3 were significantly protected
from the severe PMA-induced perturbations seen in WT embryos. Finally, embryos exposed
to elevated glucose had increased defects that were RasGRP3-dependent, showing that the
RasGRP3 status of the embryo is critical to its response to maternal glucose. Taken together,
these findings indicate that lack of Rasgrp3 function in the embryo is critical for protection
from developmental defects, and that potential maternal effects of Rasgrp3 loss do not
impact the elevated glucose levels that lead to elevated DAG and diabetes.
The finding that RasGRP3 mediates the effects of a diabetic environment on embryonic
development, including vascular development, suggests that RasGRP3 may be a new and
useful therapeutic target for prevention of diabetes-associated birth defects. The lack of
embryonic defects with Rasgrp3 loss-of-function under normal conditions (this study and 19)
indicates that blockade of RasGRP3 is not detrimental to overall development. The focus of
this study was analysis of gain- and loss-of-function for RasGRP3 in developing vessels and
endothelial cells, and we show that RasGRP3-mediated signaling uses Ras/ERK as a target
and mediates ET1 effects on angiogenesis. It will be interesting to determine whether
RasGRP3-mediated signaling is important in adult vascular pathologies.
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NON-STANDARD ABBREVIATIONS
RasGRP3 Ras guanyl-releasing protein 3
DAG diacylglycerol
PLCγ phospholipase C gamma
VEGF-A vascular endothelial growth factor-A
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PKC protein kinase C
GEF guanine nucleotide exchange factor
p38 MAPK p38 map kinase
JNK C-jun N-terminal kinase
PECAM platelet endothelial cell adhesion molecule
PMA phorbol 12-myristate 13-acetate
WT wild-type
HUVEC human umbilical vein endothelial cells
GFP green fluorescent protein
STZ streptozotocin
VE-cadherin vascular endothelial-cadherin
ICAM-2 intercellular adhesion molecule-2
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--Diabetes leads to elevation of diacylglycerol and endothelin and blood vessel
dysfunction
--Maternal diabetes leads to birth defects
--Diacylglycerol activates RasGRP3 (Ras guanyl releasing protein 3) a mediator of
cell signaling
What new information does this article contribute?
--The Ras activator RasGRP3 mediates birth defects associated with diabetes
--RasGRP3 affects the migration of endothelial cells that form blood vessels
--RasGRP3 is required for major vessel responses to diacylglycerol and endothelin
This study focused on the Ras activator, RasGRP3, in blood vessel disruptions induced
by diabetes. We show that a lack of RasGRP3 protects mouse embryos from diabetes-
induced birth defects in blood vessels and other tissues. Endothelial cells expressing
activated RasGRP3 had elevated levels of active Ras and ERK. Endothelial cells lacking
RasGRP3 did not activate Ras or ERK in response to a surrogate of diacylglycerol, PMA
(phorbol 12-myristate 13-acetate) or endothelin-1. Endothelin-mediated endothelial cell
proliferation, migration, and blood vessel formation were attenuated in vessels lacking
RasGRP3. Thus RasGRP3 is necessary and sufficient for the activation of Ras signaling
in endothelial cells and in developing blood vessels in response to signals that are
elevated in diabetes. Moreover, RasGRP3 is required for the full spectrum of vascular
and non-vascular birth defects induced by diabetes. Our work for the first time
demonstrates a critical role for RasGRP3 in the complications of diabetes, and link
between RasGRP3 and endothelin-mediated signaling. It also defines Ras as a RasGRP3
target in endothelial cells. This work advances our understanding of pathways that
mediate diabetic complications, and is significant in suggesting that RasGRP3 may be a
novel therapeutic target for fetal complications induced by diabetes.
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Figure 1. Loss of RasGRP3 attenuates diabetes-induced developmental defects
WT (A, B, G, K) and Rasgrp3gt/gt (C, D, H, L) E9.5 embryos were isolated from mothers
made diabetic with STZ (B, D, G, H, K, L), or isolated from Ins2Akita (E, I, M) or Ins2Akita;
Rasgrp3gt/gt (F,J, N) diabetic mothers and stained for PECAM. (A) WT embryos from non-
diabetic WT mothers have few defects, while (B) WT embryos from diabetic mothers have
defects in the somitic vasculature (arrow), head plexus (arrow), and somites; (C)
Rasgrp3gt/gt embryos from Rasgrp3gt/gt non-diabetic mothers have few defects, and (D)
Rasgrp3gt/gt embryos from Rasgrp3gt/gt diabetic mothers are also relatively normal. (E)
Embryos from Ins2Akita; Rasgrp3+/+ mothers have somitic vessel and head plexus defects
(arrows), whereas (F) embryos from Ins2Akita; Rasgrp3gt/gt mothers have few defects. (G-J)
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Close-up of somitic regions of embryos of indicated genotypes; (K-N) close-up of head
plexus regions of embryos of indicated genotypes. Arrows point to defects in vascular
pattern. (O) The developmental severity index was calculated on groups of embryos as
described in Methods. Mother's genotype and diabetic status: Lane 1, WT non-diabetic (n =
46); Lane 2, WT STZ diabetic (n = 51); Lane 3, Rasgrp3gt/gt non-diabetic (n = 25); Lane 4,
Rasgrp3gt/gt STZ diabetic (n = 27); Lane 5, Ins2Akita; Rasgrp3+/+ diabetic (n = 17); Lane 6,
Ins2Akita; Rasgrp3gt/gt diabetic (n = 19). **, p≤0.001 for WT vs. WT-STZ diabetic; ***,
p≤0.00001 for WT vs. Ins2Akita; ##, p≤0.0001 for Ins2Akita; Rasgrp3+/+ vs. Ins2Akita;
Rasgrp3gt/gt.
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Figure 2. Over-expression of activated RasGRP3 activates Ras and ERK in endothelial cells
(A) HUVEC were transiently transfected with the constructs shown. (B) IB for GFP linked
to RasGRP3 constructs (top panel) shows relative expression of the introduced genes; Ras-
GTP panel is a Ras blot of Ras-RBD (Raf Binding Domain) immunoprecipitation to show
activated Ras; Ras panel is 10% loading of input to show total Ras; pERK panel is blot
hybridized with p-ERK (activated); ERK is total ERK blot. Lane 1, HUVEC transfected
with GFP control; Lane 2, HUVEC transfected with GFP-RasGRP3; Lane 3; HUVEC
transfected with GFP-RasGRP3-KCAAX; Lane 4; HUVEC transfected with GFP-
RasGRP3-HCAAX. (C) Relative increase in reactivity for active Ras/total Ras (top panel) or
active ERK/total ERK (bottom panel) relative to GFP control. *, p≤0.01; **, p≤0.002; ***,
p≤0.0001, relative to the relevant control.
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Figure 3. Over-expression of active RasGRP3 perturbs the actin cytoskeleton and migration of
endothelial cells
(A-H), HUVEC transfected with the indicated constructs were incubated for 48 hr, then
fixed and imaged for GFP (green) (A-D) or stained with phalloidin (red) (B-H). (A-B)
control GFP-CAAX; (C-D) GFP-RasGRP3; (E-F) GFP-RasGRP3-KCAAX; (G-H) GFP-
RasGRP3-HCAAX. Astericks in panels E-H indicate transfected cells with perturbed
phalloidin staining. (I-J), HUVEC were labeled with cell-tracker and live imaged. (I)
HUVEC expressing GFP-RasGRP3 (green) and labeled with celltracker (red); (J) diagram
showing how the average velocity (V) and distance from origin (D) were calculated from
cell trajectories; (K) average velocity; (L) average distance from origin. **, p≤0.005; ***,
p≤0.0001, relative to control.
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Figure 4. RasGRP3 is required for Ras-ERK activation downstream of phorbol ester and ET1
but not VEGF-A
(A) WT and Rasgrp3gt/gt endothelial cells were treated with PMA and processed for Ras and
ERK activation. Compared to WT endothelial cells, Rasgrp3gt/gt endothelial cells did not
show increased activated Ras (Ras-GTP) and had an attenuated activation of pERK. (B) WT
and Rasgrp3gt/gt endothelial cells were treated with ET1 or VEGF-A and processed for Ras
activation. WT endothelial cells had increased levels of activated Ras (Ras-GTP) in response
to both VEGF and ET1, whereas Rasgrp3gt/gt endothelial cells had increased activated Ras
(Ras-GTP) in response to VEGF-A but an attenuated response to ET1. (C) WT and
Rasgrp3gt/gt endothelial cells were stimulated with ET1 or VEGF-A and processed for ERK
activation. WT endothelial cells had increased levels of pERK in response to both VEGF
and ET1, whereas Rasgrp3gt/gt endothelial cells had increased pERK in response to VEGF-
A but not in response to ET1. Experiments are representative of at least 3 replicates.
Randhawa et al. Page 18













Figure 5. RasGRP3 mediates ET1-induced endothelial cell proliferation and migration
Control (A, C) or ET1-treated (B, D) WT (A, B) or Rasgrp3gt/gt (C, D) endothelial cells
were stained for PECAM (green) and PH3 (red). (E) Representative areas were imaged and
mitotic cells counted. The relative mitotic index was significantly increased in WT
endothelial cells treated with ET1, but was not significantly increased in Rasgrp3gt/gt
endothelial cells treated with ET1. **, p ≤ 0.001 relative to WT untreated; ###, p ≤ 0.001
relative to ET1-treated WT endothelial cells. (F) Transwell migration assays. WT
endothelial cells had significantly increased migration towards both ET1 and VEGF-A
compared to control, whereas Rasgrp3gt/gt endothelial cells had significantly increased
migration towards VEGF-A but not towards ET1. *, p ≤ 0.01 relative to untreated; **, p ≤
0.0001 relative to untreated; ##, p ≤ 0.0001, Rasgrp3gt/gt ET-1 treated vs. WT ET1-treated.
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Figure 6. RasGRP3 mediates ET1-induced vessel dysmorphogenesis
ES cell cultures that were WT (A, B) or Rasgrp3gt/gt (C, D) were untreated (A, C) or treated
with ET1 (B, D), then fixed and stained for PECAM (green) on day 8. (E) Representative
images were quantified for vascular area. WT vessels treated with ET1 had significantly
increased vascular area, whereas ET-1 treated Rasgrp3gt/gt vessels did not have increased
vascular area. **, p ≤ 0.01 relative to control.
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Figure 7. Model of activated RasGRP3 signaling and function in endothelial cells
In this model, maternal diabetic conditions induce elevated DAG production in embryos via
aberrant glucose metabolism and via ET1 signaling; endothelial RasGRP3 is over-activated
by DAG and PKC phosphorylation to activate Ras (Ras-GTP). Ras signaling through MEK/
ERK affects the endothelial actin cytoskeleton and perturbs migration, leading to
developmental defects.
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